691889-35-7

Upstream product

• 36438-64-9 p-benzyloxystyrene 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 199393-31-2 (R)-2-(tert-butoxycarbonyl)amino-2-(4-benzyloxyphenyl)ethanol 
• 4248-19-5 tert-butyl carbazate 
• 27460-85-1 N-(tert-butoxycarbonyl)-D-(4-hydroxyphenyl)glycine 
• 37763-23-8 D-2-p-hydroxyphenylglycine methyl ester 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 57591-61-4 methyl (R)-2-amino-2-(4-hydroxyphenyl)acetate hydrochloride 
• 586413-61-8 (R)-N-(t-butoxycarbonyl)-4-(t-butyldimethylsiloxy)phenylglycine methyl ester 
• 143323-49-3 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 

Downstream Products

• 420110-45-8 (R)-4-(1-amino-2-hydroxyethyl)phenol 
• 906552-95-2 [1-(4-{4'-[4-(1-tert-butoxycarbonylamino-2-hydroxy-ethyl)-phenoxy]-1,1'-dioxy-[2,2']bipyridinyl-4-yloxy}-phenyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester 
• 1286280-51-0 {(R)-2-hydroxy-1-[4-((S)-2-methyl-butoxy)phenyl]ethyl}carbamic acid t-butyl ester 
• 1286280-78-1 tert-butyl (R)-2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-1-(4-((S)-2-methylbutoxy)phenyl)ethylcarbamate 
• 1286280-73-6 (2R)-2-amino-2-[4-(2-methylpentyloxy)phenyl]ethanol hydrochloride 
• 1286280-79-2 (1S,2S)-2-thiophen-2-yl-cyclopropanecarboxylic acid {(R)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-1-[4-((S)-2-methyl-butoxy)phenyl]ethyl}amide 
• 1286280-41-8 (1S,2S)-2-thiophen-2-yl-cyclopropanecarboxylic acid {(R)-2-hydroxy-1-[4-(2-methyl-pentyloxy)phenyl]ethyl}amide 
• 1286280-43-0 (1S,2S)-2-thiophen-2-yl-cyclopropanecarboxylic acid {(R)-2-amino-1-[4-((S)-2-methyl-butoxy)phenyl]ethyl}amide 
• 1286280-52-1 {(R)-2-hydroxy-1-[4-((S)-2-methyl-butoxy)phenyl]ethyl}amine hydrochloride 
• 1286280-32-7 (1S,2S)-thiophen-2-yl-cyclopropanecarboxylic acid {(R)-2-hydroxy-1-[4-((S)-2-methyl-butoxy)phenyl]ethyl}amide 
• 1286280-72-5 tert-butyl (1R)-2-hydroxy-1-[4-(2-methylpentyloxy)phenyl]ethylcarbamate 
• 1454273-77-8 (R)-2-((tert-butoxycarbonyl)amino)-2-(4-(2-ethylacetoxy)phenyl)ethyl methanesulfonate 
• 1454273-78-9 (R)-ethyl 2-(4-(1-((tert-butoxycarbonyl)amino)-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenoxy)acetate 
• 1454273-79-0 (R)-ethyl 2-(4-(1-amino-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenoxy)acetate 

Relevant academic research and scientific papers

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases incl

APOPTOSIS-INDUCING AGENTS

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides gonadotropin releasing hormone receptor antagonists and the pharmaceutical composition comprising the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease

MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.

BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Biphenyl derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the H3 histamine receptor. (Ia) Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness, such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.

Chiral borromeates

The fellowship of the rings: Circular dichroism measurements reveal that chirality is transferred from 12 stereogenic centers to 6 octahedral zinc(II) centers (see picture) in two enantiomeric pairs of chiral Borromeates, one of which has been found to be

BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of tricyclic compounds that are useful as such agents.

The anandamide membrane transporter. Structurea€"activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region

A new series of arachidonic and oleic acids derivatives, most of which with aromatic moieties in the head group region, has been synthesized and evaluated as inhibitors of anandamide uptake. A new series of anandamide and N-oleoylethanolamine analogs, most of which with aromatic moieties in the head group region, has been synthesized and evaluated as inhibitors of anandamide uptake. Some of them efficaciously inhibit the uptake process with Ki values in the low micromolar range (2.4-21.2 μM). Strict structural requisites are needed to observe a significant inhibition and in no case inhibition of fatty acid amidohydrolase overlaps with inhibition of anandamide uptake.

A Reactivity/Affinity Switch for Parallel Kinetic Resolution: α-Amino Acid Quasienantiomers and the Resolution of Cyclopropene Carboxylic Acids

A new type of parallel kinetic resolution (PKR) is reported in which quasienantiomers with very similar reactivities give products whose chromatographic properties diverge upon the addition of fluoride. This concept of a reactivity/affinity switch is applied to the PKR of cyclopropene carboxylic acids with all-carbon quaternary centers. This is the first application of α-amino acid quasienantiomers in PKR, and it is a complementary approach for acyltransfer systems where the asymmetry is induced by the nucleophile rather than the leaving group. Excellent diastereoselectivities (ranging from 90:10 to 99.5:5) and good yields were obtained for both quasienantiomeric products, and the reactions can be run on significant scale because the separation is trivial. High-level DFT calculations (B3LYP functional with the 6-31+G(d,p) basis set) provided transition-state structures with relative energies that are in accord with the experimental observations. Copyright

Mono and sequential bis solid phase alkylations of a (R)-phenylglycinol derived pyrrolidinone scaffold

The preparation of piperidine- and pyrrolidinone-like polymer supported (R)-phenylglycinol derived scaffolds is described. Alkylation reactions were performed as a model transformation of these templates on the solid support which highlight some specific